Entrada Therapeutics, Inc. (TRDA) Tops Q4 EPS by 70c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q4 EPS of $0.03, $0.70 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $37.4 million versus the consensus estimate of $13.34 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• iQIYI (IQ) Misses Q2 EPS by 21c